Femstat 3 goes OTC

Published on .

The Food & Drug Administration has granted over-the-counter approval to Femstat 3, a treatment for vaginal yeast infections. The product is a joint venture of Procter & Gamble Co. and Roche Holding. Its claimed advantage is that it works in three days rather than the seven days of similar products, such as Johnson & Johnson's Monistat 7, the market leader. Femstat 3 will reach retail stores by spring and will receive ad support through Leo Burnett USA, Chicago.

Most Popular
In this article: